Abstract
Severe asthma is a heterogeneous disease with a variety of different phenotypes and endotypes. Biomarkers may facilitate the diagnosis and classification of severe asthma, predict efficacy of specific therapies, and assess medication response. Pulmonary function testing is an essential biomarker for the diagnosis and management of asthma. Recently, spirometric parameters reflecting small-airway obstruction have shown promise in the diagnosis and management of certain phenotypes of asthma. In addition, the presence of potential asthma biomarkers has been examined in a variety of biological samples including exhaled breath, blood, sputum, bronchoalveolar lavage fluid, bronchial brushings, bronchial biopsies, and urine. Biomarker candidates identified in these samples include fractional exhaled nitric oxide, eosinophils, neutrophils, IgE, cytokines, chemokines, and bioactive molecules. Despite the progress made in the identification of potential biomarkers for severe asthma, further studies are still needed to standardize collection methods, quantify measurement, and assess clinical significance of candidate biomarkers. Meanwhile, with the ongoing advancement in technologies related to proteomics, genomics, and metabolomics, the potential exists to discover more and more candidate biomarkers that will ultimately aid in the diagnosis and treatment of severe asthma.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
The ENFUMOSA. cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J. 2003;22(3):470–7.
Pride NB, Permutt S, Riley RL, Bromberger-Barnea B. Determinants of maximal expiratory flow from the lungs. J Appl Physiol. 1967;23(5):646–62.
Mead J, Turner JM, Macklem PT, Little JB. Significance of the relationship between lung recoil and maximum expiratory flow. J Appl Physiol. 1967;22(1):95–108.
Gelb AF, Zamel N. Unsuspected pseudophysiologic emphysema in chronic persistent asthma. Am J Respir Crit Care Med. 2000;162(5):1778–82.
Woolcock AJ, Read J. The static elastic properties of the lungs in asthma. Am Rev Respir Dis. 1968;98(5):788–94.
Gelb AF, Schein A, Nussbaum E, Shinar CM, Aelony Y, Aharonian H, et al. Risk factors for near-fatal asthma. Chest. 2004;126(4):1138–46.
Sorkness RL, Bleecker ER, Busse WW, Calhoun WJ, Castro M, Chung KF, et al. Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. J Appl Physiol. 2008;104(2):394–403.
Perez T, Chanez P, Dusser D, Devillier P. Prevalence and reversibility of lung hyperinflation in adult asthmatics with poorly controlled disease or significant dyspnea. Allergy. 2016;71(1):108–14.
Gibbons WJ, Sharma A, Lougheed D, Macklem PT. Detection of excessive bronchoconstriction in asthma. Am J Respir Crit Care Med. 1996;153(2):582–9.
Chapman DG, Berend N, Horlyck KR, King GG, Salome CM. Does increased baseline ventilation heterogeneity following chest wall strapping predispose to airway hyperresponsiveness? J Appl Physiol. 2012;113(1):25–30.
Kaminsky DA, Daud A, Chapman DG. Relationship between the baseline alveolar volume-to-total lung capacity ratio and airway responsiveness. Respirology. 2014;19(7):1046–51.
Bourdin A, Paganin F, Prefaut C, Kieseler D, Godard P, Chanez P. Nitrogen washout slope in poorly controlled asthma. Allergy. 2006;61(1):85–9.
Porsbjerg C, Rasmussen L, Nolte H, Backer V. Association of airway hyperresponsiveness with reduced quality of life in patients with moderate to severe asthma. Ann Allergy Asthma Immunol. 2007;98(1):44–50.
Thamrin C, Nydegger R, Stern G, Chanez P, Wenzel SE, Watt RA, et al. Associations between fluctuations in lung function and asthma control in two populations with differing asthma severity. Thorax. 2011;66(12):1036–42.
Wenzel S. Physiologic and pathologic abnormalities in severe asthma. Clin Chest Med. 2006;27(1):29–40. v
Shi Y, Aledia AS, Galant SP, George SC. Peripheral airway impairment measured by oscillometry predicts loss of asthma control in children. J Allergy Clin Immunol. 2013;131(3):718–23.
Lutchen KR, Jensen A, Atileh H, Kaczka DW, Israel E, Suki B, et al. Airway constriction pattern is a central component of asthma severity: the role of deep inspirations. Am J Respir Crit Care Med. 2001;164(2):207–15.
Bates JH, Irvin CG, Farre R, Hantos Z. Oscillation mechanics of the respiratory system. Compr Physiol. 2011;1(3):1233–72.
Sferrazza Papa GF, Pellegrino GM, Pellegrino R. Asthma and respiratory physiology: putting lung function into perspective. Respirology. 2014;19(7):960–9.
Alfieri V, Aiello M, Pisi R, Tzani P, Mariani E, Marangio E, et al. Small airway dysfunction is associated to excessive bronchoconstriction in asthmatic patients. Respir Res. 2014;15:86.
Kelly VJ, Sands SA, Harris RS, Venegas JG, Brown NJ, Stuart-Andrews CR, et al. Respiratory system reactance is an independent determinant of asthma control. J Appl Physiol. 2013;115(9):1360–9.
Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–73.
Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. Am Rev Respir Dis 1987;136(1):225–44.
A plea to abandon asthma as a disease concept. Lancet. 2006;368(9537):705.
Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178(3):218–24.
Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010;181(4):315–23.
Fitzpatrick AM, Teague WG, Meyers DA, Peters SP, Li X, Li H, et al. Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. J Allergy Clin Immunol. 2011;127(2):382–9 e1-13.
Schatz M, Hsu JW, Zeiger RS, Chen W, Dorenbaum A, Chipps BE, et al. Phenotypes determined by cluster analysis in severe or difficult-to-treat asthma. J Allergy Clin Immunol. 2014;133(6):1549–56.
Konstantellou E, Papaioannou AI, Loukides S, Patentalakis G, Papaporfyriou A, Hillas G, et al. Persistent airflow obstruction in patients with asthma: characteristics of a distinct clinical phenotype. Respir Med. 2015;109(11):1404–9.
Schatz M, Rosenwasser L. The allergic asthma phenotype. J Allergy Clin Immunol Pract. 2014;2(6):645–8. quiz 9
(GINA) GIfA. Diagnosis of diseases of chronic airflow limitation: asthma, COPD and Asthma-COPD Overlap Syndrome (ACOS). Global Strategy for Asthma Management and Prevention; 2014.
Gibson PG, McDonald VM. Asthma-COPD overlap 2015: now we are six. Thorax. 2015;70(7):683–91.
Finkelstein JA, Lozano P, Shulruff R, Inui TS, Soumerai SB, Ng M, et al. Self-reported physician practices for children with asthma: are national guidelines followed? Pediatrics. 2000;106(4 Suppl):886–96.
(GINA) GIfA. Pocket guide for asthma management and prevention (A pocket guide for health professionals updated 2016); 2016.
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–38.
Expert panel Report 2: guidelines for the diagnosis and management of asthma (EPR-2 1997). NIH Publication No. 97-4051. Bethesda, MD: U.S. Department of Health and Human Services; National Institutes of Health; National Heart, Lung, and Blood Institutes; National Asthma Education and Prevention Program; 1997.
Bacharier LB, Strunk RC, Mauger D, White D, Lemanske RF Jr, Sorkness CA. Classifying asthma severity in children: mismatch between symptoms, medication use, and lung function. Am J Respir Crit Care Med. 2004;170(4):426–32.
Paull K, Covar R, Jain N, Gelfand EW, Spahn JD. Do NHLBI lung function criteria apply to children? A cross-sectional evaluation of childhood asthma at National Jewish Medical and Research Center, 1999-2002. Pediatr Pulmonol. 2005;39(4):311–7.
Strunk RC, Weiss ST, Yates KP, Tonascia J, Zeiger RS, Szefler SJ, et al. Mild to moderate asthma affects lung growth in children and adolescents. J Allergy Clin Immunol. 2006;118(5):1040–7.
Group TCAMPR. Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl J Med. 2000;343(15):1054–63.
Fitzpatrick AM, Gaston BM, Erzurum SC, Teague WG, National Institutes of Health/National Heart L, Blood Institute Severe Asthma Research P. Features of severe asthma in school-age children: atopy and increased exhaled nitric oxide. J Allergy Clin Immunol. 2006;118(6):1218–25.
Simon MR, Chinchilli VM, Phillips BR, Sorkness CA, Lemanske RF Jr, Szefler SJ, et al. Forced expiratory flow between 25% and 75% of vital capacity and FEV1/forced vital capacity ratio in relation to clinical and physiological parameters in asthmatic children with normal FEV1 values. J Allergy Clin Immunol. 2010;126(3):527–34 e1-8.
Perez T, Chanez P, Dusser D, Devillier P. Small airway impairment in moderate to severe asthmatics without significant proximal airway obstruction. Respir Med. 2013;107(11):1667–74.
Quanjer PH, Weiner DJ, Pretto JJ, Brazzale DJ, Boros PW. Measurement of FEF25-75% and FEF75% does not contribute to clinical decision making. Eur Respir J. 2014;43(4):1051–8.
Rao DR, Gaffin JM, Baxi SN, Sheehan WJ, Hoffman EB, Phipatanakul W. The utility of forced expiratory flow between 25% and 75% of vital capacity in predicting childhood asthma morbidity and severity. J Asthma. 2012;49(6):586–92.
Riley CM, Wenzel SE, Castro M, Erzurum SC, Chung KF, Fitzpatrick AM, et al. Clinical implications of having reduced mid forced expiratory flow rates (FEF25-75), independently of FEV1, in adult patients with asthma. PLoS One. 2015;10(12):e0145476.
Siroux V, Boudier A, Dolgopoloff M, Chanoine S, Bousquet J, Gormand F, et al. Forced midexpiratory flow between 25% and 75% of forced vital capacity is associated with long-term persistence of asthma and poor asthma outcomes. J Allergy Clin Immunol. 2016;137(6):1709–16. e6
Francisco B, Ner Z, Ge B, Hewett J, Konig P. Sensitivity of different spirometric tests for detecting airway obstruction in childhood asthma. J Asthma. 2015;52(5):505–11.
Mottram C. Ruppel’s manual of pulmonary function testing. 10th ed. Amsterdam: Elsevier; 2012.
Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A. 1987;84(24):9265–9.
Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature. 1988;333(6174):664–6.
Dweik RA, Comhair SA, Gaston B, Thunnissen FB, Farver C, Thomassen MJ, et al. NO chemical events in the human airway during the immediate and late antigen-induced asthmatic response. Proc Natl Acad Sci U S A. 2001;98(5):2622–7.
Ricciardolo FL. Multiple roles of nitric oxide in the airways. Thorax. 2003;58(2):175–82.
Khatri SB, Hammel J, Kavuru MS, Erzurum SC, Dweik RA. Temporal association of nitric oxide levels and airflow in asthma after whole lung allergen challenge. J Appl Physiol. 2003;95(1):436–40. discussion 5
Khatri SB, Ozkan M, McCarthy K, Laskowski D, Hammel J, Dweik RA, et al. Alterations in exhaled gas profile during allergen-induced asthmatic response. Am J Respir Crit Care Med. 2001;164(10 Pt 1):1844–8.
Guo FH, De Raeve HR, Rice TW, Stuehr DJ, Thunnissen FB, Erzurum SC. Continuous nitric oxide synthesis by inducible nitric oxide synthase in normal human airway epithelium in vivo. Proc Natl Acad Sci U S A. 1995;92(17):7809–13.
Guo FH, Erzurum SC. Characterization of inducible nitric oxide synthase expression in human airway epithelium. Environ Health Perspect. 1998;106(Suppl 5):1119–24.
Guo FH, Uetani K, Haque SJ, Williams BR, Dweik RA, Thunnissen FB, et al. Interferon gamma and interleukin 4 stimulate prolonged expression of inducible nitric oxide synthase in human airway epithelium through synthesis of soluble mediators. J Clin Invest. 1997;100(4):829–38.
Guo FH, Comhair SA, Zheng S, Dweik RA, Eissa NT, Thomassen MJ, et al. Molecular mechanisms of increased nitric oxide (NO) in asthma: evidence for transcriptional and post-translational regulation of NO synthesis. J Immunol. 2000;164(11):5970–80.
Alving K, Weitzberg E, Lundberg JM. Increased amount of nitric oxide in exhaled air of asthmatics. Eur Respir J. 1993;6(9):1368–70.
Kharitonov SA, Yates D, Robbins RA, Logan-Sinclair R, Shinebourne EA, Barnes PJ. Increased nitric oxide in exhaled air of asthmatic patients. Lancet. 1994;343(8890):133–5.
Gaston B, Drazen J, Chee CBE, Wohl MEB, Stamler JS. Expired nitric oxide concentrations are elevated in patients with reactive airways disease. Endothelium. 1993;1:87–92.
Jouaville LF, Annesi-Maesano I, Nguyen LT, Bocage AS, Bedu M, Caillaud D. Interrelationships among asthma, atopy, rhinitis and exhaled nitric oxide in a population-based sample of children. Clin Exp Allergy. 2003;33(11):1506–11.
Silkoff PE, McClean P, Spino M, Erlich L, Slutsky AS, Zamel N. Dose-response relationship and reproducibility of the fall in exhaled nitric oxide after inhaled beclomethasone dipropionate therapy in asthma patients. Chest. 2001;119(5):1322–8.
Dweik RA, Erzurum SC. Regulation of nitric oxide (NO) synthases and gas phase NO by oxygen. In: Marczin N, Kharitonov SA, Yacoub MH, Barnes PJ, editors. Disease markers in exhaled breath (lung biology in health and disease). New York: Marcel Dekker, Inc; 2003. p. 235–46.
Hansel TT, Kharitonov SA, Donnelly LE, Erin EM, Currie MG, Moore WM, et al. A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics. FASEB J. 2003;17(10):1298–300.
Gustafsson LE, Leone AM, Persson MG, Wiklund NP, Moncada S. Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and humans. Biochem Biophys Res Commun. 1991;181(2):852–7.
Ricciardolo FL, Di Stefano A, Silvestri M, Van Schadewijk AM, Malerba M, Hiemstra PS, et al. Exhaled nitric oxide is related to bronchial eosinophilia and airway hyperresponsiveness to bradykinin in allergen-induced asthma exacerbation. Int J Immunopathol Pharmacol. 2012;25(1):175–82.
Covar RA, Szefler SJ, Martin RJ, Sundstrom DA, Silkoff PE, Murphy J, et al. Relations between exhaled nitric oxide and measures of disease activity among children with mild-to-moderate asthma. J Pediatr. 2003;142(5):469–75.
Smith AD, Cowan JO, Taylor DR. Exhaled nitric oxide levels in asthma: personal best versus reference values. J Allergy Clin Immunol. 2009;124(4):714–8. e4
Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184(5):602–15.
Kotaniemi-Syrjanen A, Malmberg LP, Malmstrom K, Pelkonen AS, Makela MJ. Factors associated with elevated exhaled nitric oxide fraction in infants with recurrent respiratory symptoms. Eur Respir J. 2013;41(1):189–94.
Singer F, Luchsinger I, Inci D, Knauer N, Latzin P, Wildhaber JH, et al. Exhaled nitric oxide in symptomatic children at preschool age predicts later asthma. Allergy. 2013;68(4):531–8.
Chien JW, Lin CY, Yang KD, Lin CH, Kao JK, Tsai YG. Increased IL-17A secreting CD4+ T cells, serum IL-17 levels and exhaled nitric oxide are correlated with childhood asthma severity. Clin Exp Allergy. 2013;43(9):1018–26.
Kawamatawong T, Siripongpun S, Rerkpattanapipat T. Role of eosinophilic inflammation and atopy in elderly asthmatic patients. Asia Pac Allergy. 2016;6(3):181–6.
Dweik RA, Sorkness RL, Wenzel S, Hammel J, Curran-Everett D, Comhair SA, et al. Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma. Am J Respir Crit Care Med. 2010;181(10):1033–41.
Amelink M, de Groot JC, de Nijs SB, Lutter R, Zwinderman AH, Sterk PJ, et al. Severe adult-onset asthma: a distinct phenotype. J Allergy Clin Immunol. 2013;132(2):336–41.
Bousquet J, Mantzouranis E, Cruz AA, Ait-Khaled N, Baena-Cagnani CE, Bleecker ER, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol. 2010;126(5):926–38.
Lodrup Carlsen KC, Hedlin G, Bush A, Wennergren G, de Benedictis FM, De Jongste JC, et al. Assessment of problematic severe asthma in children. Eur Respir J. 2011;37(2):432–40.
de Andrade WC, Lasmar LM, Ricci Cde A, Camargos PA, Cruz AA. Phenotypes of severe asthma among children and adolescents in Brazil: a prospective study. BMC Pulm Med. 2015;15:36.
Sharples J, Gupta A, Fleming L, Bossley CJ, Bracken-King M, Hall P, et al. Long-term effectiveness of a staged assessment for paediatric problematic severe asthma. Eur Respir J. 2012;40(1):264–7.
Konradsen JR, Nordlund B, Lidegran M, Pedroletti C, Gronlund H, van Hage M, et al. Problematic severe asthma: a proposed approach to identifying children who are severely resistant to therapy. Pediatr Allergy Immunol. 2011;22(1 Pt 1):9–18.
Silkoff PE, Lent AM, Busacker AA, Katial RK, Balzar S, Strand M, et al. Exhaled nitric oxide identifies the persistent eosinophilic phenotype in severe refractory asthma. J Allergy Clin Immunol. 2005;116(6):1249–55.
Tseliou E, Bessa V, Hillas G, Delimpoura V, Papadaki G, Roussos C, et al. Exhaled nitric oxide and exhaled breath condensate pH in severe refractory asthma. Chest. 2010;138(1):107–13.
Michils A, Baldassarre S, Van Muylem A. Exhaled nitric oxide and asthma control: a longitudinal study in unselected patients. Eur Respir J. 2008;31(3):539–46.
Jones SL, Kittelson J, Cowan JO, Flannery EM, Hancox RJ, McLachlan CR, et al. The predictive value of exhaled nitric oxide measurements in assessing changes in asthma control. Am J Respir Crit Care Med. 2001;164(5):738–43.
Gelb AF, Flynn Taylor C, Shinar CM, Gutierrez C, Zamel N. Role of spirometry and exhaled nitric oxide to predict exacerbations in treated asthmatics. Chest. 2006;129(6):1492–9.
van der Valk RJ, Baraldi E, Stern G, Frey U, de Jongste JC. Daily exhaled nitric oxide measurements and asthma exacerbations in children. Allergy. 2012;67(2):265–71.
Brzozowska A, Majak P, Jerzynska J, Smejda K, Bobrowska-Korzeniowska M, Stelmach W, et al. Exhaled nitric oxide correlates with IL-2, MCP-1, PDGF-BB and TIMP-2 in exhaled breath condensate of children with refractory asthma. Postepy Dermatol Alergol. 2015;32(2):107–13.
Gomersal T, Harnan S, Essat M, Tappenden P, Wong R, Lawson R, et al. A systematic review of fractional exhaled nitric oxide in the routine management of childhood asthma. Pediatr Pulmonol. 2016;51(3):316–28.
Pike K, Selby A, Price S, Warner J, Connett G, Legg J, et al. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid dose in paediatric asthma: a randomised controlled trial. Clin Respir J. 2013;7(2):204–13.
Peirsman EJ, Carvelli TJ, Hage PY, Hanssens LS, Pattyn L, Raes MM, et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. Pediatr Pulmonol. 2014;49(7):624–31.
Petsky HL, Li AM, Au CT, Kynaston JA, Turner C, Chang AB. Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: a dual centre randomized controlled trial. Pediatr Pulmonol. 2015;50(6):535–43.
Shaw DE, Berry MA, Hargadon B, McKenna S, Shelley MJ, Green RH, et al. Association between neutrophilic airway inflammation and airflow limitation in adults with asthma. Chest. 2007;132(6):1871–5.
Szefler SJ, Mitchell H, Sorkness CA, Gergen PJ, O’Connor GT, Morgan WJ, et al. Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. Lancet. 2008;372(9643):1065–72.
Calhoun WJ, Ameredes BT, King TS, Icitovic N, Bleecker ER, Castro M, et al. Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized controlled trial. JAMA. 2012;308(10):987–97.
Petsky HL, Cates CJ, Lasserson TJ, Li AM, Turner C, Kynaston JA, et al. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax. 2012;67(3):199–208.
Essat M, Harnan S, Gomersall T, Tappenden P, Wong R, Pavord I, et al. Fractional exhaled nitric oxide for the management of asthma in adults: a systematic review. Eur Respir J. 2016;47(3):751–68.
Malerba M, Ragnoli B, Radaeli A, Ricciardolo FLM. Long-term adjustment of stable asthma treatment with fractional exhaled nitric oxide and sputum eosinophils. Eur J Inflamm. 2012;10(3):383–92.
Gibson PG. Using fractional exhaled nitric oxide to guide asthma therapy: design and methodological issues for ASthma TReatment ALgorithm studies. Clin Exp Allergy. 2009;39(4):478–90.
Cowan DC, Taylor DR, Peterson LE, Cowan JO, Palmay R, Williamson A, et al. Biomarker-based asthma phenotypes of corticosteroid response. J Allergy Clin Immunol. 2015;135(4):877–83.e1.
Kharitonov SA, Yates DH, Barnes PJ. Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. Am J Respir Crit Care Med. 1996;153(1):454–7.
Parulekar AD, Diamant Z, Hanania NA. Role of T2 inflammation biomarkers in severe asthma. Curr Opin Pulm Med. 2016;22(1):59–68.
Silkoff PE, Laviolette M, Singh D, FitzGerald JM, Kelsen S, Backer V, et al. Longitudinal stability of asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study. Respir Res. 2016;17:43.
Kharitonov SA, Gonio F, Kelly C, Meah S, Barnes PJ. Reproducibility of exhaled nitric oxide measurements in healthy and asthmatic adults and children. Eur Respir J. 2003;21(3):433–8.
Ekroos H, Karjalainen J, Sarna S, Laitinen LA, Sovijarvi AR. Short-term variability of exhaled nitric oxide in young male patients with mild asthma and in healthy subjects. Respir Med. 2002;96(11):895–900.
Thijs W, de Mutsert R, le Cessie S, Hiemstra PS, Rosendaal FR, Middeldorp S, et al. Reproducibility of exhaled nitric oxide measurements in overweight and obese adults. BMC Res Notes. 2014;7:775.
Buchvald F, Eiberg H, Bisgaard H. Heterogeneity of FeNO response to inhaled steroid in asthmatic children. Clin Exp Allergy. 2003;33(12):1735–40.
Hanania NA, Wenzel S, Rosen K, Hsieh HJ, Mosesova S, Choy DF, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187(8):804–11.
Sorkness CA, Wildfire JJ, Calatroni A, Mitchell HE, Busse WW, O’Connor GT, et al. Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents. J Allergy Clin Immunol Pract. 2013;1(2):163–71.
Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368(26):2455–66.
Luo J, Liu D, Liu CT. The efficacy and safety of antiinterleukin 13, a monoclonal antibody, in adult patients with asthma: a systematic review and meta-analysis. Medicine. 2016;95(6):e2556.
American Thoracic S, European RS. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005;171(8):912–30.
Olin AC, Bake B, Toren K. Fraction of exhaled nitric oxide at 50 mL/s: reference values for adult lifelong never-smokers. Chest. 2007;131(6):1852–6.
Olin AC, Rosengren A, Thelle DS, Lissner L, Bake B, Toren K. Height, age, and atopy are associated with fraction of exhaled nitric oxide in a large adult general population sample. Chest. 2006;130(5):1319–25.
Grob NM, Dweik RA. Exhaled nitric oxide in asthma. From diagnosis, to monitoring, to screening: are we there yet? Chest. 2008;133(4):837–9.
Buchvald F, Baraldi E, Carraro S, Gaston B, De Jongste J, Pijnenburg MW, et al. Measurements of exhaled nitric oxide in healthy subjects age 4 to 17 years. J Allergy Clin Immunol. 2005;115(6):1130–6.
Olivieri M, Talamini G, Corradi M, Perbellini L, Mutti A, Tantucci C, et al. Reference values for exhaled nitric oxide (reveno) study. Respir Res. 2006;7:94.
Travers J, Marsh S, Aldington S, Williams M, Shirtcliffe P, Pritchard A, et al. Reference ranges for exhaled nitric oxide derived from a random community survey of adults. Am J Respir Crit Care Med. 2007;176(3):238–42.
Dressel H, de la Motte D, Reichert J, Ochmann U, Petru R, Angerer P, et al. Exhaled nitric oxide: independent effects of atopy, smoking, respiratory tract infection, gender and height. Respir Med. 2008;102(7):962–9.
Kovesi T, Kulka R, Dales R. Exhaled nitric oxide concentration is affected by age, height, and race in healthy 9- to 12-year-old children. Chest. 2008;133(1):169–75.
Wong GW, Liu EK, Leung TF, Yung E, Ko FW, Hui DS, et al. High levels and gender difference of exhaled nitric oxide in Chinese schoolchildren. Clin Exp Allergy. 2005;35(7):889–93.
Malmberg LP, Petays T, Haahtela T, Laatikainen T, Jousilahti P, Vartiainen E, et al. Exhaled nitric oxide in healthy nonatopic school-age children: determinants and height-adjusted reference values. Pediatr Pulmonol. 2006;41(7):635–42.
Jacinto T, Alving K, Correia R, Costa-Pereira A, Fonseca J. Setting reference values for exhaled nitric oxide: a systematic review. Clin Respir J. 2013;7(2):113–20.
Ludviksdottir D, Diamant Z, Alving K, Bjermer L, Malinovschi A. Clinical aspects of using exhaled NO in asthma diagnosis and management. Clin Respir J. 2012;6(4):193–207.
Saito J, Sato S, Fukuhara A, Sato Y, Nikaido T, Inokoshi Y, et al. Association of asthma education with asthma control evaluated by asthma control test, FEV1, and fractional exhaled nitric oxide. J Asthma. 2013;50(1):97–102.
Horvath I, Hunt J, Barnes PJ, Alving K, Antczak A, Baraldi E, et al. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J. 2005;26(3):523–48.
Kietzmann D, Kahl R, Muller M, Burchardi H, Kettler D. Hydrogen peroxide in expired breath condensate of patients with acute respiratory failure and with ARDS. Intensive Care Med. 1993;19(2):78–81.
Effros RM, Hoagland KW, Bosbous M, Castillo D, Foss B, Dunning M, et al. Dilution of respiratory solutes in exhaled condensates. Am J Respir Crit Care Med. 2002;165(5):663–9.
Scheideler L, Manke HG, Schwulera U, Inacker O, Hammerle H. Detection of nonvolatile macromolecules in breath. A possible diagnostic tool? Am Rev Respir Dis. 1993;148(3):778–84.
Melo REPT, Solé D. <Exhaled breath temperature, a new biomarker in asthma control: a pilot study>. J Bras Pneumol. 2010;36(6):693–9.
Garcia G, Bergna M, Uribe E, Yanez A, Soriano JB. Increased exhaled breath temperature in subjects with uncontrolled asthma. Int J Tuberc Lung Dis. 2013;17(7):969–72.
Leonardi S, Cuppari C, Lanzafame A, Attardo D, Tardino L, Parisi G, et al. Exhaled breath temperature in asthmatic children. J Biol Regul Homeost Agents. 2015;29(2 Suppl 1):47–54.
Piacentini GL, Peroni D, Crestani E, Zardini F, Bodini A, Costella S, Boner AL. Exhaled air temperature in asthma: methods and relationship with markers of disease. Clin Exp Allergy. 2007;37(3):415–9.
Paredi P, Kharitonov SA, Barnes PJ. Correlation of exhaled breath temperature with bronchial blood flow in asthma. Respir Res. 2005;6:15.
Piacentini GLPD, Bodini A, Corradi M, Boner AL. Exhaled breath temperature as a marker of airway remodelling in asthma: a preliminary study. Allergy. 2008;63(4):484–5.
Crespo Lessmann A, Giner J, Torrego A, Mateus E, Torrejon M, Belda A, et al. Usefulness of the exhaled breath temperature plateau in asthma patients. Respiration. 2015;90(2):111–7.
Hamill L, Ferris K, Kapande K, McConaghy L, Douglas I, McGovern V, et al. Exhaled breath temperature measurement and asthma control in children prescribed inhaled corticosteroids: a cross sectional study. Pediatr Pulmonol. 2016;51(1):13–21.
Svensson H, Bjermer L, Tufvesson E. Exhaled breath temperature in asthmatics and controls after eucapnic voluntary hyperventilation and a methacholine challenge test. Respiration. 2014;87(2):149–57.
Vermeulen S, Barreto M, La Penna F, Prete A, Martella S, Biagiarelli F, et al. Exhaled breath temperature in children: reproducibility and influencing factors. J Asthma. 2014;51(7):743–50.
Barreto M, Piacentini G, Chiossi L, Ruggeri F, Caiazzo I, Campisano M, et al. Tidal-breathing measurement of exhaled breath temperature (EBT) in schoolchildren. Pediatr Pulmonol. 2014;49(12):1196–204.
Prince PBM, Boulet LP. A fast, simple, and inexpensive method to collect exhaled breath condensate for pH determination. Ann Allergy Asthma Immunol. 2006;97(5):622–7.
Paget-Brown AO, Ngamtrakulpanit L, Smith A, Bunyan D, Hom S, Nguyen A, et al. Normative data for pH of exhaled breath condensate. Chest. 2006;129(2):426–30.
Effros RM, Casaburi R, Porszasz J, Rehan V. Why conventional exhaled breath condensate pH studies cannot provide reliable estimates of airway acidification. Chest. 2011;140(4):1099.
Hunt JF, Fang K, Malik R, Snyder A, Malhotra N, Platts-Mills TA, Gaston B. Endogenous airway acidification. Implications for asthma pathophysiology. Am J Respir Crit Care Med. 2000;161(3 Pt 1):694–9.
Antus B, Barta I, Kullmann T, Lazar Z, Valyon M, Horvath I, et al. Assessment of exhaled breath condensate pH in exacerbations of asthma and chronic obstructive pulmonary disease: a longitudinal study. Am J Respir Crit Care Med. 2010;182(12):1492–7.
Fitzpatrick AM, Holbrook JT, Wei CY, Brown MS, Wise RA, Teague WG, et al. Exhaled breath condensate pH does not discriminate asymptomatic gastroesophageal reflux or the response to lansoprazole treatment in children with poorly controlled asthma. J Allergy Clin Immunol Pract. 2014;2(5):579–86.e7.
Bikov A, Galffy G, Tamasi L, Lazar Z, Losonczy G, Horvath I. Exhaled breath condensate pH is influenced by respiratory droplet dilution. J Breath Res. 2012;6(4):046002.
Liu L, Teague WG, Erzurum S, Fitzpatrick A, Mantri S, Dweik RA, et al. Determinants of exhaled breath condensate pH in a large population with asthma. Chest. 2011;139(2):328–36.
Leung TF, Li CY, Yung E, Liu EK, Lam CW, Wong GW. Clinical and technical factors affecting pH and other biomarkers in exhaled breath condensate. Pediatr Pulmonol. 2006;41(1):87–94.
von Jagwitz M, Pessler F, Akmatov M, Li J, Range U, Vogelberg C. Reduced breath condensate pH in asymptomatic children with prior wheezing as a risk factor for asthma. J Allergy Clin Immunol. 2011;128(1):50–5.
Caffarelli C, Dascola CP, Peroni D, Rico S, Stringari G, Varini M, et al. Airway acidification in childhood asthma exacerbations. Allergy Asthma Proc. 2014;35(3):51–6.
Tomasiak-Lozowska MM, Zietkowski Z, Przeslaw K, Tomasiak M, Skiepko R, Bodzenta-Lukaszyk A. Inflammatory markers and acid-base equilibrium in exhaled breath condensate of stable and unstable asthma patients. Int Arch Allergy Immunol. 2012;159(2):121–9.
Kane B, Borrill Z, Southworth T, Woodcock A, Singh D. Reduced exhaled breath condensate pH in asthmatic smokers using inhaled corticosteroids. Respirology. 2009;14(3):419–23.
Davies KJ. Oxidative stress: the paradox of aerobic life. Biochem Soc Symp. 1995;61:1–31.
Conner EM, Grisham MB. Inflammation, free radicals, and antioxidants. Nutrition. 1996;12(4):274–7.
Jöbsis Q, Raatgeep HC, Hermans PW, de Jongste JC. Hydrogen peroxide in exhaled air is increased in stable asthmatic children. Eur Respir J. 1997;10(3):519–21.
Antczak A, Nowak D, Shariati B, Król M, Piasecka G, Kurmanowska Z. Increased hydrogen peroxide and thiobarbituric acid-reactive products in expired breath condensate of asthmatic patients. Eur Respir J. 1997;10(6):1235–41.
Emelyanov A, Fedoseev G, Abulimity A, Rudinski K, Fedoulov A, Karabanov A, et al. Elevated concentrations of exhaled hydrogen peroxide in asthmatic patients. Chest. 2001;120(4):1136–9.
Loukides S, Bouros D, Papatheodorou G, Panagou P, Siafakas NM. The relationships among hydrogen peroxide in expired breath condensate, airway inflammation, and asthma severity. Chest. 2002;121(2):338–46.
Al-Obaidy AH, Al-Samarai AG. Exhaled breath condensate pH and hydrogen peroxide as non-invasive markers for asthma. Saudi Med J. 2007;28(12):1860–3.
Caffarelli C, Calcinai E, Rinaldi L, Povesi Dascola C, Terracciano L, Corradi M. Hydrogen peroxide in exhaled breath condensate in asthmatic children during acute exacerbation and after treatment. Respiration. 2012;84(4):291–8.
Murata K, Fujimoto K, Kitaguchi Y, Horiuchi T, Kubo K, Honda T. Hydrogen peroxide content and pH of expired breath condensate from patients with asthma and COPD. COPD. 2014;11(1):81–7.
Warwick G, Thomas PS, Yates DH. Non-invasive biomarkers in exacerbations of obstructive lung disease. Respirology. 2013;18(5):874–84.
Trischler J, Merkel N, Konitzer S, Muller CM, Unverzagt S, Lex C. Fractionated breath condensate sampling: H(2)O(2) concentrations of the alveolar fraction may be related to asthma control in children. Respir Res. 2012;13:14.
Al Obaidi AH, Al Samarai AM. Biochemical markers as a response guide for steroid therapy in asthma. J Asthma. 2008;45(5):425–8.
Teng Y, Sun P, Zhang J, Yu R, Bai J, Yao X, et al. Hydrogen peroxide in exhaled breath condensate in patients with asthma: a promising biomarker? Chest. 2011;140(1):108–16.
Robroeks CM, van Vliet D, Jobsis Q, Braekers R, Rijkers GT, Wodzig WK, et al. Prediction of asthma exacerbations in children: results of a one-year prospective study. Clin Exp Allergy. 2012;42(5):792–8.
Sood A, Qualls C, Seagrave J, McDonald J, Shohreh R, Chiavaroli A, et al. Effect of allergen inhalation on airway oxidant stress, using exhaled breath condensate 8-isoprostane, in mild asthma. J Asthma. 2013;50(5):449–56.
Koskela HO, Purokivi MK, Nieminen RM, Moilanen E. Asthmatic cough and airway oxidative stress. Respir Physiol Neurobiol. 2012;181(3):346–50.
Montuschi P, Corradi M, Ciabattoni G, Nightingale J, Kharitonov SA, Barnes PJ. Increased 8-isoprostane, a marker of oxidative stress, in exhaled condensate of asthma patients. Am J Respir Crit Care Med. 1999;160(1):216–20.
Baraldi E, Ghiro L, Piovan V, Carraro S, Ciabattoni G, Barnes PJ, et al. Increased exhaled 8-isoprostane in childhood asthma. Chest. 2003;124(1):25–31.
Mondino C, Ciabattoni G, Koch P, Pistelli R, Trove A, Barnes PJ, et al. Effects of inhaled corticosteroids on exhaled leukotrienes and prostanoids in asthmatic children. J Allergy Clin Immunol. 2004;114(4):761–7.
Zanconato S, Carraro S, Corradi M, Alinovi R, Pasquale MF, Piacentini G, et al. Leukotrienes and 8-isoprostane in exhaled breath condensate of children with stable and unstable asthma. J Allergy Clin Immunol. 2004;113(2):257–63.
Shahid SK, Kharitonov SA, Wilson NM, Bush A, Barnes PJ. Exhaled 8-isoprostane in childhood asthma. Respir Res. 2005;6:79.
Samitas K, Chorianopoulos D, Vittorakis S, Zervas E, Economidou E, Papatheodorou G, et al. Exhaled cysteinyl-leukotrienes and 8-isoprostane in patients with asthma and their relation to clinical severity. Respir Med. 2009;103(5):750–6.
Caballero Balanzá S, Martorell Aragonés A, Cerdá Mir JC, Belda RamÃrez J, Navarro Iváñez R, Navarro Soriano A, et al. Leukotriene B4 and 8-isoprostane in exhaled breath condensate of children with episodic and persistent asthma. J Investig Allergol Clin Immunol. 2010;20(3):237–43.
Hasan RA, O’Brien E, Mancuso P. Lipoxin A(4) and 8-isoprostane in the exhaled breath condensate of children hospitalized for status asthmaticus. Pediatr Crit Med. 2012;13(2):141–5.
Carraro S, Cogo PE, Isak I, Simonato M, Corradi M, Carnielli VP, et al. EIA and GC/MS analysis of 8-isoprostane in EBC of children with problematic asthma. Eur Respir J. 2010;35(6):1364–9.
Keskin O, Balaban S, Keskin M, Kucukosmanoglu E, Gogebakan B, Ozkars MY, et al. Relationship between exhaled leukotriene and 8-isoprostane levels and asthma severity, asthma control level, and asthma control test score. Allergol Immunopathol. 2014;42(3):191–7.
Brussino L, Badiu I, Sciascia S, Bugiani M, Heffler E, Guida G, et al. Oxidative stress and airway inflammation after allergen challenge evaluated by exhaled breath condensate analysis. Clin Exp Allergy. 2010;40(11):1642–7.
Piotrowski WJ, Majewski S, Marczak J, Kurmanowska Z, Gorski P, Antczak A. Exhaled breath 8-isoprostane as a marker of asthma severity. Arch Med Sci. 2012;8(3):515–20.
Keskin O, Uluca U, Keskin M, Gogebakan B, Kucukosmanoglu E, Ozkars MY, et al. The efficacy of single-high dose inhaled corticosteroid versus oral prednisone treatment on exhaled leukotriene and 8-isoprostane levels in mild to moderate asthmatic children with asthma exacerbation. Allergol Immunopathol. 2016;44(2):138–48.
Liu J, Thomas PS. Exhaled breath condensate as a method of sampling airway nitric oxide and other markers of inflammation. Med Sci Monit. 2005;11(8):MT53–62.
Ganas K, Loukides S, Papatheodorou G, Panagou P, Kalogeropoulos N. Total nitrite/nitrate in expired breath condensate of patients with asthma. Respir Med. 2001;95(8):649–54.
Corradi M, Pesci A, Casana R, Alinovi R, Goldoni M, Vettori MV, et al. Nitrate in exhaled breath condensate of patients with different airway diseases. Nitric Oxide. 2003;8(1):26–30.
Ratnawati, Morton J, Henry RL, Thomas PS. Exhaled breath condensate nitrite/nitrate and pH in relation to pediatric asthma control and exhaled nitric oxide. Pediatr Pulmonol. 2006;41(10):929–36.
Zetterquist W, Marteus H, Hedlin G, Alving K. Increased exhaled nitrite in children with allergic asthma is not related to nitric oxide formation. Clin Respir J. 2008;2(3):166–74.
Bouzigon E, Monier F, Boussaha M, Le Moual N, Huyvaert H, Matran R, et al. Associations between nitric oxide synthase genes and exhaled NO-related phenotypes according to asthma status. PLoS One. 2012;7(5):e36672.
Hauswirth DW, Sundy JS, Mervin-Blake S, Fernandez CA, Patch KB, Alexander KM, et al. Normative values for exhaled breath condensate pH and its relationship to exhaled nitric oxide in healthy African Americans. J Allergy Clin Immunol. 2008;122(1):101–6.
Rihak V, Zatloukal P, Chladkova J, Zimulova A, Havlinova Z, Chladek J. Nitrite in exhaled breath condensate as a marker of nitrossative stress in the airways of patients with asthma, COPD, and idiopathic pulmonary fibrosis. J Clin Lab Anal. 2010;24(5):317–22.
Malinovschi A, Pizzimenti S, Sciascia S, Heffler E, Badiu I, Rolla G. Exhaled breath condensate nitrates, but not nitrites or FENO, relate to asthma control. Respir Med. 2011;105(7):1007–13.
Scott JA, North ML, Rafii M, Huang H, Pencharz P, Subbarao P, et al. Asymmetric dimethylarginine is increased in asthma. Am J Respir Crit Care Med. 2011;184(7):779–85.
Carraro S, Giordano G, Piacentini G, Kantar A, Moser S, Cesca L, et al. Asymmetric dimethylarginine in exhaled breath condensate and serum of children with asthma. Chest. 2013;144(2):405–10.
Samuelsson B, Granstrom E, Green K, Hamberg M, Hammarstrom S. Prostaglandins. Annu Rev Biochem. 1975;44:669–95.
Montuschi P, Barnes PJ. Analysis of exhaled breath condensate for monitoring airway inflammation. Trends Pharmacol Sci. 2002;23(5):232–7.
Montuschi P, Barnes PJ. Exhaled leukotrienes and prostaglandins in asthma. J Allergy Clin Immunol. 2002;109(4):615–20.
Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science. 1983;220(4597):568–75.
Montuschi P, Sala A, Dahlen S-E, Folco G. Pharmacological modulation of the leukotriene pathway in allergic airway disease. Drug Discov Today. 2007;12:404.
Wardlaw AJ, Hay H, Cromwell O, Collins JV, Kay AB. Leukotrienes, LTC4 and LTB4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases. J Allergy Clin Immunol. 1989;84(1):19–26.
Claesson HE, Odlander B, Jakobsson PJ. Leukotriene B4 in the immune system. Int J Immunopharmacol. 1992;14(3):441–9.
Hallstrand TS, Henderson WR Jr. An update on the role of leukotrienes in asthma. Curr Opin Allergy Clin Immunol. 2010;10(1):60–6.
Holgate ST, Peters-Golden M, Panettieri RA, Henderson WR Jr. Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. J Allergy Clin Immunol. 2003;111(1 Suppl):S18–34. discussion S-6
Ono E, Mita H, Taniguchi M, Higashi N, Tsuburai T, Hasegawa M, et al. Increase in inflammatory mediator concentrations in exhaled breath condensate after allergen inhalation. J Allergy Clin Immunol. 2008;122(4):768–73.e1.
Antczak A, Montuschi P, Kharitonov S, Gorski P, Barnes PJ. Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma. Am J Respir Crit Care Med. 2002;166(3):301–6.
Montuschi P, Mondino C, Koch P, Barnes PJ, Ciabattoni G. Effects of a leukotriene receptor antagonist on exhaled leukotriene E4 and prostanoids in children with asthma. J Allergy Clin Immunol. 2006;118(2):347–53.
Kielbasa B, Moeller A, Sanak M, Hamacher J, Hutterli M, Cmiel A, et al. Eicosanoids in exhaled breath condensates in the assessment of childhood asthma. Pediatr Allergy Immunol. 2008;19(7):660–9.
Hanazawa T, Kharitonov SA, Barnes PJ. Increased nitrotyrosine in exhaled breath condensate of patients with asthma. Am J Respir Crit Care Med. 2000;162(4 Pt 1):1273–6.
Cap P, Chladek J, Pehal F, Maly M, Petru V, Barnes PJ, et al. Gas chromatography/mass spectrometry analysis of exhaled leukotrienes in asthmatic patients. Thorax. 2004;59(6):465–70.
Baraldi E, Carraro S, Alinovi R, Pesci A, Ghiro L, Bodini A, et al. Cysteinyl leukotrienes and 8-isoprostane in exhaled breath condensate of children with asthma exacerbations. Thorax. 2003;58(6):505–9.
Laberge S, El Bassam S. Cytokines, structural cells of the lungs and airway inflammation. Paediatr Respir Rev. 2004;5(Suppl A):S41–5.
Shahid SK, Kharitonov SA, Wilson NM, Bush A, Barnes PJ. Increased interleukin-4 and decreased interferon-gamma in exhaled breath condensate of children with asthma. Am J Respir Crit Care Med. 2002;165(9):1290–3.
Carpagnano GE, Resta O, Ventura MT, Amoruso AC, Di Gioia G, Giliberti T, et al. Airway inflammation in subjects with gastro-oesophageal reflux and gastro-oesophageal reflux-related asthma. J Intern Med. 2006;259(3):323–31.
Robroeks CM, van de Kant KD, Jobsis Q, Hendriks HJ, van Gent R, Wouters EF, et al. Exhaled nitric oxide and biomarkers in exhaled breath condensate indicate the presence, severity and control of childhood asthma. Clin Exp Allergy. 2007;37(9):1303–11.
Profita M, La Grutta S, Carpagnano E, Riccobono L, Di Giorgi R, Bonanno A, et al. Noninvasive methods for the detection of upper and lower airway inflammation in atopic children. J Allergy Clin Immunol. 2006;118(5):1068–74.
Carpagnano GE, Foschino Barbaro MP, Cagnazzo M, Di Gioia G, Giliberti T, Di Matteo C, et al. Use of exhaled breath condensate in the study of airway inflammation after hypertonic saline solution challenge. Chest. 2005;128(5):3159–66.
Matsunaga K, Yanagisawa S, Ichikawa T, Ueshima K, Akamatsu K, Hirano T, et al. Airway cytokine expression measured by means of protein array in exhaled breath condensate: correlation with physiologic properties in asthmatic patients. J Allergy Clin Immunol. 2006;118(1):84–90.
Ojoo JC, Mulrennan SA, Kastelik JA, Morice AH, Redington AE. Exhaled breath condensate pH and exhaled nitric oxide in allergic asthma and in cystic fibrosis. Thorax. 2005;60(1):22–6.
Gluck J, Rymarczyk B, Kasprzak M, Rogala B. Increased levels of interleukin-33 and thymic stromal lymphopoietin in exhaled breath condensate in chronic bronchial asthma. Int Arch Allergy Immunol. 2016;169(1):51–6.
Zietkowski Z, Skiepko R, Tomasiak MM, Bodzenta-Lukaszyk A. Endothelin-1 in exhaled breath condensate of stable and unstable asthma patients. Respir Med. 2008;102(3):470–4.
Zietkowski Z, Tomasiak MM, Skiepko R, Bodzenta-Lukaszyk A. RANTES in exhaled breath condensate of stable and unstable asthma patients. Respir Med. 2008;102(8):1198–202.
Zietkowski Z, Tomasiak-Lozowska MM, Skiepko R, Zietkowska E, Bodzenta-Lukaszyk A. Eotaxin-1 in exhaled breath condensate of stable and unstable asthma patients. Respir Res. 2010;11:110.
Wu D, Zhou J, Bi H, Li L, Gao W, Huang M, et al. CCL11 as a potential diagnostic marker for asthma? J Asthma. 2014;51(8):847–54.
Huszar E, Vass G, Vizi E, Csoma Z, Barat E, Molnar Vilagos G, et al. Adenosine in exhaled breath condensate in healthy volunteers and in patients with asthma. Eur Respir J. 2002;20(6):1393–8.
Greenwald R, Fitzpatrick AM, Gaston B, Marozkina NV, Erzurum S, Teague WG. Breath formate is a marker of airway S-nitrosothiol depletion in severe asthma. PLoS One. 2010;5(7):e11919.
Simpson JL, Scott RJ, Boyle MJ, Gibson PG. Differential proteolytic enzyme activity in eosinophilic and neutrophilic asthma. Am J Respir Crit Care Med. 2005;172(5):559–65.
Corradi M, Folesani G, Andreoli R, Manini P, Bodini A, Piacentini G, et al. Aldehydes and glutathione in exhaled breath condensate of children with asthma exacerbation. Am J Respir Crit Care Med. 2003;167(3):395–9.
Zietkowski Z, Tomasiak-Lozowska MM, Skiepko R, Mroczko B, Szmitkowski M, Bodzenta-Lukaszyk A. High-sensitivity C-reactive protein in the exhaled breath condensate and serum in stable and unstable asthma. Respir Med. 2009;103(3):379–85.
Grob NM, Aytekin M, Dweik RA. Biomarkers in exhaled breath condensate: a review of collection, processing and analysis. J Breath Res. 2008;2(3):037004.
Bloemen K, Van Den Heuvel R, Govarts E, Hooyberghs J, Nelen V, Witters E, et al. A new approach to study exhaled proteins as potential biomarkers for asthma. Clin Exp Allergy. 2011;41(3):346–56.
Bartoli ML, Novelli F, Costa F, Malagrino L, Melosini L, Bacci E, et al. Malondialdehyde in exhaled breath condensate as a marker of oxidative stress in different pulmonary diseases. Mediat Inflamm. 2011;2011:891752.
Motta A, Paris D, D’Amato M, Melck D, Calabrese C, Vitale C, et al. NMR metabolomic analysis of exhaled breath condensate of asthmatic patients at two different temperatures. J Proteome Res. 2014;13(12):6107–20.
Klaassen EM, van de Kant KD, Jobsis Q, Penders J, van Schooten FJ, Quaak M, et al. Integrative genomic analysis identifies a role for intercellular adhesion molecule 1 in childhood asthma. Pediatr Allergy Immunol. 2014;25(2):166–72.
Miekisch W, Schubert JK, Noeldge-Schomburg GF. Diagnostic potential of breath analysis—focus on volatile organic compounds. Clin Chim Acta. 2004;347(1–2):25–39.
Buszewski B, Kesy M, Ligor T, Amann A. Human exhaled air analytics: biomarkers of diseases. Biomedical Chromatogr. 2007;21(6):553–66.
van de Kant KD, van der Sande LJ, Jobsis Q, van Schayck OC, Dompeling E. Clinical use of exhaled volatile organic compounds in pulmonary diseases: a systematic review. Respir Res. 2012;13:117.
Olopade CO, Zakkar M, Swedler WI, Rubinstein I. Exhaled pentane levels in acute asthma. Chest. 1997;111(4):862–5.
Caldeira M, Perestrelo R, Barros AS, Bilelo MJ, Morete A, Camara JS, et al. Allergic asthma exhaled breath metabolome: a challenge for comprehensive two-dimensional gas chromatography. J Chromatogr A. 2012;1254:87–97.
Smolinska A, Klaassen EM, Dallinga JW, van de Kant KD, Jobsis Q, Moonen EJ, et al. Profiling of volatile organic compounds in exhaled breath as a strategy to find early predictive signatures of asthma in children. PLoS One. 2014;9(4):e95668.
Dragonieri S, Schot R, Mertens BJ, Le Cessie S, Gauw SA, Spanevello A, et al. An electronic nose in the discrimination of patients with asthma and controls. J Allergy Clin Immunol. 2007;120(4):856–62.
Paredi P, Kharitonov SA, Barnes PJ. Elevation of exhaled ethane concentration in asthma. Am J Respir Crit Care Med. 2000;162(4 Pt 1):1450–4.
Fens N, Zwinderman AH, van der Schee MP, de Nijs SB, Dijkers E, Roldaan AC, et al. Exhaled breath profiling enables discrimination of chronic obstructive pulmonary disease and asthma. Am J Respir Crit Care Med. 2009;180(11):1076–82.
Timms C, Thomas PS, Yates DH. Detection of gastro-oesophageal reflux disease (GORD) in patients with obstructive lung disease using exhaled breath profiling. J Breath Res. 2012;6(1):016003.
Delfino RJ, Gong H, Linn WS, Hu Y, Pellizzari ED. Respiratory symptoms and peak expiratory flow in children with asthma in relation to volatile organic compounds in exhaled breath and ambient air. J Expo Anal Environ Epidemiol. 2003;13(5):348–63.
Robroeks CM, van Berkel JJ, Jobsis Q, van Schooten FJ, Dallinga JW, Wouters EF, et al. Exhaled volatile organic compounds predict exacerbations of childhood asthma in a 1-year prospective study. Eur Respir J. 2013;42(1):98–106.
van der Schee MP, Palmay R, Cowan JO, Taylor DR. Predicting steroid responsiveness in patients with asthma using exhaled breath profiling. Clin Exp Allergy. 2013;43(11):1217–25.
Sly PD, Boner AL, Bjorksten B, Bush A, Custovic A, Eigenmann PA, et al. Early identification of atopy in the prediction of persistent asthma in children. Lancet. 2008;372(9643):1100–6.
Simpson A, Tan VY, Winn J, Svensen M, Bishop CM, Heckerman DE, et al. Beyond atopy: multiple patterns of sensitization in relation to asthma in a birth cohort study. Am J Respir Crit Care Med. 2010;181(11):1200–6.
Stoltz DJ, Jackson DJ, Evans MD, Gangnon RE, Tisler CJ, Gern JE, et al. Specific patterns of allergic sensitization in early childhood and asthma & rhinitis risk. Clin Exp Allergy. 2013;43(2):233–41.
Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest. 2004;125(4):1378–86.
Wahn U, Martin C, Freeman P, Blogg M, Jimenez P. Relationship between pretreatment specific IgE and the response to omalizumab therapy. Allergy. 2009;64(12):1780–7.
Szefler SJ, Wenzel S, Brown R, Erzurum SC, Fahy JV, Hamilton RG, et al. Asthma outcomes: biomarkers. J Allergy Clin Immunol. 2012;129(3 Suppl):S9–23.
Peters MC, Mekonnen ZK, Yuan S, Bhakta NR, Woodruff PG, Fahy JV. Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma. J Allergy Clin Immunol. 2014;133(2):388–94.
Tran TN, Khatry DB, Ke X, Ward CK, Gossage D. High blood eosinophil count is associated with more frequent asthma attacks in asthma patients. Ann Allergy Asthma Immunol. 2014;113(1):19–24.
Ulrik CS, Frederiksen J. Mortality and markers of risk of asthma death among 1,075 outpatients with asthma. Chest. 1995;108(1):10–5.
Malinovschi A, Fonseca JA, Jacinto T, Alving K, Janson C. Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects. J Allergy Clin Immunol. 2013;132(4):821–7 e1-5.
Ulrik CS. Peripheral eosinophil counts as a marker of disease activity in intrinsic and extrinsic asthma. Clin Exp Allergy. 1995;25(9):820–7.
Taylor KJ, Luksza AR. Peripheral blood eosinophil counts and bronchial responsiveness. Thorax. 1987;42(6):452–6.
Szefler SJ, Phillips BR, Martinez FD, Chinchilli VM, Lemanske RF, Strunk RC, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol. 2005;115(2):233–42.
Kupczyk M, Haque S, Middelveld RJ, Dahlen B, Dahlen SE, Investigators B. Phenotypic predictors of response to oral glucocorticosteroids in severe asthma. Respir Med. 2013;107(10):1521–30.
Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014;2(11):879–90.
Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–207.
Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–9.
Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–97.
Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360(10):985–93.
Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184(10):1125–32.
Busse W, Spector S, Rosén K, Wang Y, Alpan O. High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects. J Allergy Clin Immunol. 2013;132(2):485–6.e11.
Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360(10):973–84.
Leckie MJ, ten Brinke A, Khan J, Diamant Z, O’Connor BJ, Walls CM, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000;356(9248):2144–8.
Gauthier M, Ray A, Wenzel SE. Evolving concepts of asthma. Am J Respir Crit Care Med. 2015;192(6):660–8.
Takayama G, Arima K, Kanaji T, Toda S, Tanaka H, Shoji S, et al. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol. 2006;118(1):98–104.
Sidhu SS, Yuan S, Innes AL, Kerr S, Woodruff PG, Hou L, et al. Roles of epithelial cell-derived periostin in TGF-beta activation, collagen production, and collagen gel elasticity in asthma. Proc Natl Acad Sci U S A. 2010;107(32):14170–5.
Woodruff PG, Boushey HA, Dolganov GM, Barker CS, Yang YH, Donnelly S, et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci U S A. 2007;104(40):15858–63.
Yuyama N, Davies DE, Akaiwa M, Matsui K, Hamasaki Y, Suminami Y, et al. Analysis of novel disease-related genes in bronchial asthma. Cytokine. 2002;19(6):287–96.
Lopez-Guisa JM, Powers C, File D, Cochrane E, Jimenez N, Debley JS. Airway epithelial cells from asthmatic children differentially express proremodeling factors. J Allergy Clin Immunol. 2012;129(4):990–7. e6
Blanchard C, Mingler MK, McBride M, Putnam PE, Collins MH, Chang G, et al. Periostin facilitates eosinophil tissue infiltration in allergic lung and esophageal responses. Mucosal Immunol. 2008;1(4):289–96.
Conway SJ, Izuhara K, Kudo Y, Litvin J, Markwald R, Ouyang G, et al. The role of periostin in tissue remodeling across health and disease. Cell Mol Life Sci. 2014;71(7):1279–88.
Jia G, Erickson RW, Choy DF, Mosesova S, Wu LC, Solberg OD, et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol. 2012;130(3):647–54. e10
Kanemitsu Y, Matsumoto H, Izuhara K, Tohda Y, Kita H, Horiguchi T, et al. Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids. J Allergy Clin Immunol. 2013;132(2):305–12. e3
Hanania NA, Noonan M, Corren J, Korenblat P, Zheng Y, Fischer SK, et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015;70(8):748–56.
Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365(12):1088–98.
Masuoka M, Shiraishi H, Ohta S, Suzuki S, Arima K, Aoki S, et al. Periostin promotes chronic allergic inflammation in response to Th2 cytokines. J Clin Invest. 2012;122(7):2590–600.
Matsumoto H. Serum periostin: a novel biomarker for asthma management. Allergol Int. 2014;63(2):153–60.
Izuhara K, Matsumoto H, Ohta S, Ono J, Arima K, Ogawa M. Recent developments regarding periostin in bronchial asthma. Allergol Int. 2015;64(Suppl):S3–10.
Bobolea I, Barranco P, Del Pozo V, Romero D, Sanz V, Lopez-Carrasco V, et al. Sputum periostin in patients with different severe asthma phenotypes. Allergy. 2015;70(5):540–6.
Gorska K, Maskey-Warzechowska M, Nejman-Gryz P, Korczynski P, Prochorec-Sobieszek M, Krenke R. Comparative study of periostin expression in different respiratory samples in patients with asthma and chronic obstructive pulmonary disease. Pol Arch Med Wewn. 2016;126(3):124–37.
Patil SP, Wisnivesky JP, Busse PJ, Halm EA, Li XM. Detection of immunological biomarkers correlated with asthma control and quality of life measurements in sera from chronic asthmatic patients. Ann Allergy Asthma Immunol. 2011;106(3):205–13.
Saad-El-Din Bessa S, Abo El-Magd GH, Mabrouk MM. Serum chemokines RANTES and monocyte chemoattractant protein-1 in Egyptian patients with atopic asthma: relationship to disease severity. Arch Med Res. 2012;43(1):36–41.
Chambers ES, Nanzer AM, Pfeffer PE, Richards DF, Timms PM, Martineau AR, et al. Distinct endotypes of steroid-resistant asthma characterized by IL-17A(high) and IFN-gamma(high) immunophenotypes: potential benefits of calcitriol. J Allergy Clin Immunol. 2015;136(3):628–37. e4
Ciprandi G, Cuppari C, Salpietro AM, Tosca MA, Rigoli L, Grasso L, et al. Serum IL-23 strongly and inversely correlates with FEV1 in asthmatic children. Int Arch Allergy Immunol. 2012;159(2):183–6.
Sziksz E, Kozma GT, Pallinger E, Komlosi ZI, Adori C, Kovacs L, et al. Galectin-9 in allergic airway inflammation and hyper-responsiveness in mice. Int Arch Allergy Immunol. 2010;151(4):308–17.
Niki T, Tsutsui S, Hirose S, Aradono S, Sugimoto Y, Takeshita K, et al. Galectin-9 is a high affinity IgE-binding lectin with anti-allergic effect by blocking IgE-antigen complex formation. J Biol Chem. 2009;284(47):32344–52.
Katoh S, Shimizu H, Obase Y, Oomizu S, Niki T, Ikeda M, et al. Preventive effect of galectin-9 on double-stranded RNA-induced airway hyperresponsiveness in an exacerbation model of mite antigen-induced asthma in mice. Exp Lung Res. 2013;39(10):453–62.
Hsu DK, Zuberi RI, Liu FT. Biochemical and biophysical characterization of human recombinant IgE-binding protein, an S-type animal lectin. J Biol Chem. 1992;267(20):14167–74.
Di Lella S, Sundblad V, Cerliani JP, Guardia CM, Estrin DA, Vasta GR, et al. When galectins recognize glycans: from biochemistry to physiology and back again. Biochemistry. 2011;50(37):7842–57.
Newlaczyl AU, Yu LG. Galectin-3—a jack-of-all-trades in cancer. Cancer Lett. 2011;313(2):123–8.
Mauri P, Riccio AM, Rossi R, Di Silvestre D, Benazzi L, De Ferrari L, et al. Proteomics of bronchial biopsies: galectin-3 as a predictive biomarker of airway remodelling modulation in omalizumab-treated severe asthma patients. Immunol Lett. 2014;162(1 Pt A):2–10.
Mosca T, Menezes MC, Dionigi PC, Stirbulov R, Forte WC. C3 and C4 complement system components as biomarkers in the intermittent atopic asthma diagnosis. J Pediatr. 2011;87(6):512–6.
Tang H, Fang Z, Sun Y, Li B, Shi Z, Chen J, et al. YKL-40 in asthmatic patients, and its correlations with exacerbation, eosinophils and immunoglobulin E. Eur Respir J. 2010;35(4):757–60.
Specjalski K, Jassem E. YKL-40 protein is a marker of asthma. J Asthma. 2011;48(8):767–72.
Ezzat MH, Imam SS, Shaheen KY, Elbrhami EM. Serum OX40 ligand levels in asthmatic children: a potential biomarker of severity and persistence. Allergy Asthma Proc. 2011;32(4):313–8.
Tanju A, Cekmez F, Aydinoz S, Karademir F, Suleymanoglu S, Gocmen I. Association between clinical severity of childhood asthma and serum leptin levels. Indian J Pediatr. 2011;78(3):291–5.
Nishioka T, Uchida K, Meno K, Ishii T, Aoki T, Imada Y, et al. Alpha-1-antitrypsin and complement component C7 are involved in asthma exacerbation. Proteomics Clin Appl. 2008;2(1):46–54.
Rhim T, Choi YS, Nam BY, Uh ST, Park JS, Kim YH, et al. Plasma protein profiles in early asthmatic responses to inhalation allergen challenge. Allergy. 2009;64(1):47–54.
Singh A, Cohen Freue GV, Oosthuizen JL, Kam SH, Ruan J, Takhar MK, et al. Plasma proteomics can discriminate isolated early from dual responses in asthmatic individuals undergoing an allergen inhalation challenge. Proteomics Clin Appl. 2012;6(9–10):476–85.
Izbicka E, Streeper RT, Michalek JE, Louden CL, Diaz A 3rd, Campos DR. Plasma biomarkers distinguish non-small cell lung cancer from asthma and differ in men and women. Cancer Genomics Proteomics. 2012;9(1):27–35.
Verrills NM, Irwin JA, He XY, Wood LG, Powell H, Simpson JL, et al. Identification of novel diagnostic biomarkers for asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;183(12):1633–43.
Araújo L, Moreira A, Palmares C, Beltrão M, Fonseca J, Delgado L. Induced sputum in children: success determinants, safety, and cell profiles. J Investig Allergol Clin Immunol. 2011;21(3):216–21.
Dasgupta A, Nair P. When are biomarkers useful in the management of airway diseases? Pol Arch Med Wewn. 2013;123(4):183–8.
Efthimiadis A, Spanevello A, Hamid Q, Kelly MM, Linden M, Louis R, et al. Methods of sputum processing for cell counts, immunocytochemistry and in situ hybridisation. Eur Respir J Suppl. 2002;37:19s–23s.
Gershman NH, Wong HH, Liu JT, Mahlmeister MJ, Fahy JV. Comparison of two methods of collecting induced sputum in asthmatic subjects. Eur Respir J. 1996;9(12):2448–53.
Pin I, Gibson PG, Kolendowicz R, Girgis-Gabardo A, Denburg JA, Hargreave FE, et al. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax. 1992;47(1):25–9.
Pizzichini E, Pizzichini MM, Efthimiadis A, Hargreave FE, Dolovich J. Measurement of inflammatory indices in induced sputum: effects of selection of sputum to minimize salivary contamination. Eur Respir J. 1996;9(6):1174–80.
Fireman E, Toledano B, Buchner N, Stark M, Schwarz Y. Simplified detection of eosinophils in induced sputum. Inflamm Res. 2011;60(8):745–50.
Goncalves J, Pizzichini E, Pizzichini MM, Steidle LJ, Rocha CC, Ferreira SC, et al. Reliability of a rapid hematology stain for sputum cytology. J Bras Pneumol. 2014;40(3):250–8.
Wenzel SE, Schwartz LB, Langmack EL, Halliday JL, Trudeau JB, Gibbs RL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med. 1999;160(3):1001–8.
Simpson JL, Scott R, Boyle MJ, Gibson PG. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology. 2006;11(1):54–61.
Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180(1):59–99.
Belda J, Leigh R, Parameswaran K, O’Byrne PM, Sears MR, Hargreave FE. Induced sputum cell counts in healthy adults. Am J Respir Crit Care Med. 2000;161(2 Pt 1):475–8.
Louis R, Sele J, Henket M, Cataldo D, Bettiol J, Seiden L, et al. Sputum eosinophil count in a large population of patients with mild to moderate steroid-naive asthma: distribution and relationship with methacholine bronchial hyperresponsiveness. Allergy. 2002;57(10):907–12.
in’t Veen JC, Smits HH, Hiemstra PS, Zwinderman AE, Sterk PJ, Bel EH. Lung function and sputum characteristics of patients with severe asthma during an induced exacerbation by double-blind steroid withdrawal. Am J Respir Crit Care Med. 1999;160(1):93–9.
Hastie AT, Moore WC, Meyers DA, Vestal PL, Li H, Peters SP, et al. Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. J Allergy Clin Immunol. 2010;125(5):1028–36. e13
Jatakanon A, Lim S, Barnes PJ. Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med. 2000;161(1):64–72.
Woodruff PG, Khashayar R, Lazarus SC, Janson S, Avila P, Boushey HA, et al. Relationship between airway inflammation, hyperresponsiveness, and obstruction in asthma. J Allergy Clin Immunol. 2001;108(5):753–8.
Berry M, Morgan A, Shaw DE, Parker D, Green R, Brightling C, et al. Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax. 2007;62(12):1043–9.
Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax. 2002;57(10):875–9.
Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002;360(9347):1715–21.
van Rensen EL, Straathof KC, Veselic-Charvat MA, Zwinderman AH, Bel EH, Sterk PJ. Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma. Thorax. 1999;54(5):403–8.
Pizzichini MM, Pizzichini E, Clelland L, Efthimiadis A, Mahony J, Dolovich J, et al. Sputum in severe exacerbations of asthma: kinetics of inflammatory indices after prednisone treatment. Am J Respir Crit Care Med. 1997;155(5):1501–8.
Leuppi JD, Salome CM, Jenkins CR, Anderson SD, Xuan W, Marks GB, et al. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am J Respir Crit Care Med. 2001;163(2):406–12.
Deykin A, Lazarus SC, Fahy JV, Wechsler ME, Boushey HA, Chinchilli VM, et al. Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids. J Allergy Clin Immunol. 2005;115(4):720–7.
Flood-Page P, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007;176(11):1062–71.
Moore WC, Hastie AT, Li X, Li H, Busse WW, Jarjour NN, et al. Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. J Allergy Clin Immunol. 2014;133(6):1557–63.e5.
Wenzel SE, Szefler SJ, Leung DY, Sloan SI, Rex MD, Martin RJ. Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med. 1997;156(3 Pt 1):737–43.
Choi JS, Jang AS, Park JS, Park SW, Paik SH, Park JS, et al. Role of neutrophils in persistent airway obstruction due to refractory asthma. Respirology. 2012;17(2):322–9.
Schleich FN, Manise M, Sele J, Henket M, Seidel L, Louis R. Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation. BMC Pulm Med. 2013;13:11.
Cowan DC, Cowan JO, Palmay R, Williamson A, Taylor DR. Effects of steroid therapy on inflammatory cell subtypes in asthma. Thorax. 2010;65(5):384–90.
Nguyen LT, Lim S, Oates T, Chung KF. Increase in airway neutrophils after oral but not inhaled corticosteroid therapy in mild asthma. Respir Med. 2005;99(2):200–7.
Shannon J, Ernst P, Yamauchi Y, Olivenstein R, Lemiere C, Foley S, et al. Differences in airway cytokine profile in severe asthma compared to moderate asthma. Chest. 2008;133(2):420–6.
McKinley L, Alcorn JF, Peterson A, Dupont RB, Kapadia S, Logar A, et al. TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J Immunol. 2008;181(6):4089–97.
Al-Ramli W, Prefontaine D, Chouiali F, Martin JG, Olivenstein R, Lemiere C, et al. T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma. J Allergy Clin Immunol. 2009;123(5):1185–7.
Lajoie S, Lewkowich IP, Suzuki Y, Clark JR, Sproles AA, Dienger K, et al. Complement-mediated regulation of the IL-17A axis is a central genetic determinant of the severity of experimental allergic asthma. Nat Immunol. 2010;11(10):928–35.
Hastie AT, Moore WC, Li H, Rector BM, Ortega VE, Pascual RM, et al. Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects. J Allergy Clin Immunol. 2013;132(1):72–80.
Bakakos P, Schleich F, Alchanatis M, Louis R. Induced sputum in asthma: from bench to bedside. Curr Med Chem. 2011;18(10):1415–22.
Koh GC, Shek LP, Goh DY, Van Bever H, Koh DS. Eosinophil cationic protein: is it useful in asthma? A systematic review. Respir Med. 2007;101(4):696–705.
Kim CK, Callaway Z, Fletcher R, Koh YY. Eosinophil-derived neurotoxin in childhood asthma: correlation with disease severity. J Asthma. 2010;47(5):568–73.
Pavord ID, Bafadhel M. Exhaled nitric oxide and blood eosinophilia: independent markers of preventable risk. J Allergy Clin Immunol. 2013;132(4):828–9.
Jia CE, Zhang HP, Lv Y, Liang R, Jiang YQ, Powell H, et al. The Asthma Control Test and Asthma Control Questionnaire for assessing asthma control: systematic review and meta-analysis. J Allergy Clin Immunol. 2013;131(3):695–703.
Mostafa GA, Reda SM, Abd El-Aziz MM, Ahmed SA. Sputum neurokinin A in Egyptian asthmatic children and adolescents: relation to exacerbation severity. Allergy. 2008;63(9):1244–7.
Yamaguchi M, Niimi A, Matsumoto H, Ueda T, Takemura M, Matsuoka H, et al. Sputum levels of transforming growth factor-beta1 in asthma: relation to clinical and computed tomography findings. J Investig Allergol Clin Immunol. 2008;18(3):202–6.
Mattos W, Lim S, Russell R, Jatakanon A, Chung KF, Barnes PJ. Matrix metalloproteinase-9 expression in asthma: effect of asthma severity, allergen challenge, and inhaled corticosteroids. Chest. 2002;122(5):1543–52.
Saito J, Zhang Q, Hui C, Macedo P, Gibeon D, Menzies-Gow A, et al. Sputum hydrogen sulfide as a novel biomarker of obstructive neutrophilic asthma. J Allergy Clin Immunol. 2013;131(1):232–4 e1-3.
Brickey WJ, Alexis NE, Hernandez ML, Reed W, Ting JP, Peden DB. Sputum inflammatory cells from patients with allergic rhinitis and asthma have decreased inflammasome gene expression. J Allergy Clin Immunol. 2011;128(4):900–3.
Alexis NE, Soukup J, Nierkens S, Becker S. Association between airway hyperreactivity and bronchial macrophage dysfunction in individuals with mild asthma. Am J Physiol Lung Cell Mol Physiol. 2001;280(2):L369–75.
Alexis NE, Brickey WJ, Lay JC, Wang Y, Roubey RA, Ting JP, et al. Development of an inhaled endotoxin challenge protocol for characterizing evoked cell surface phenotype and genomic responses of airway cells in allergic individuals. Ann Allergy Asthma Immunol. 2008;100(3):206–15.
Loughlin CE, Esther CR Jr, Lazarowski ER, Alexis NE, Peden DB. Neutrophilic inflammation is associated with altered airway hydration in stable asthmatics. Respir Med. 2010;104(1):29–33.
Brightling CE, Symon FA, Birring SS, Bradding P, Pavord ID, Wardlaw AJ. TH2 cytokine expression in bronchoalveolar lavage fluid T lymphocytes and bronchial submucosa is a feature of asthma and eosinophilic bronchitis. J Allergy Clin Immunol. 2002;110(6):899–905.
Alexis NE, Hu SC, Zeman K, Alter T, Bennett WD. Induced sputum derives from the central airways: confirmation using a radiolabeled aerosol bolus delivery technique. Am J Respir Crit Care Med. 2001;164(10 Pt 1):1964–70.
Alexis N, Soukup J, Ghio A, Becker S. Sputum phagocytes from healthy individuals are functional and activated: a flow cytometric comparison with cells in bronchoalveolar lavage and peripheral blood. Clin Immunol. 2000;97(1):21–32.
Goleva E, Jackson LP, Harris JK, Robertson CE, Sutherland ER, Hall CF, et al. The effects of airway microbiome on corticosteroid responsiveness in asthma. Am J Respir Crit Care Med. 2013;188(10):1193–201.
Esnault S, Kelly EA, Schwantes EA, Liu LY, DeLain LP, Hauer JA, et al. Identification of genes expressed by human airway eosinophils after an in vivo allergen challenge. PLoS One. 2013;8(7):e67560.
Vargas JE, Porto BN, Puga R, Stein RT, Pitrez PM. Identifying a biomarker network for corticosteroid resistance in asthma from bronchoalveolar lavage samples. Mol Biol Rep. 2016;43(7):697–710.
Park SW, Lee EH, Lee EJ, Kim HJ, Bae DJ, Han S, et al. Apolipoprotein A1 potentiates lipoxin A4 synthesis and recovery of allergen-induced disrupted tight junctions in the airway epithelium. Clin Exp Allergy. 2013;43(8):914–27.
Sampson AP. The leukotrienes: mediators of chronic inflammation in asthma. Clin Exp Allergy. 1996;26(9):995–1004.
Montuschi P, Peters-Golden ML. Leukotriene modifiers for asthma treatment. Clin Exp Allergy. 2010;40(12):1732–41.
Montuschi P, Santini G, Valente S, Mondino C, Macagno F, Cattani P, et al. Liquid chromatography-mass spectrometry measurement of leukotrienes in asthma and other respiratory diseases. J Chromatogr B. 2014;964:12–25.
Severien C, Artlich A, Jonas S, Becher G. Urinary excretion of leukotriene E4 and eosinophil protein X in children with atopic asthma. Eur Respir J. 2000;16(4):588–92.
Suzuki N, Hishinuma T, Abe F, Omata K, Ito S, Sugiyama M, et al. Difference in urinary LTE4 and 11-dehydro-TXB2 excretion in asthmatic patients. Prostaglandins Other Lipid Mediat. 2000;62(4):395–403.
Aggarwal S, Moodley YP, Thompson PJ, Misso NL. Prostaglandin E2 and cysteinyl leukotriene concentrations in sputum: association with asthma severity and eosinophilic inflammation. Clin Exp Allergy. 2010;40(1):85–93.
Marmarinos A, Saxoni-Papageorgiou P, Cassimos D, Manoussakis E, Tsentidis C, Doxara A, et al. Urinary leukotriene E4 levels in atopic and non-atopic preschool children with recurrent episodic (viral) wheezing: a potential marker? J Asthma. 2015;52(6):554–9.
Morales M, Flores C, Pino K, Angulo J, Lopez-Lastra M, Castro-Rodriguez JA. Urinary leukotriene and Bcl I polymorphism of glucocorticoid receptor gene in preschoolers with recurrent wheezing and high risk of asthma. Allergol Immunopathol. 2016;44(1):59–65.
Chiu CY, Tsai MH, Yao TC, Tu YL, Hua MC, Yeh KW, et al. Urinary LTE4 levels as a diagnostic marker for IgE-mediated asthma in preschool children: a birth cohort study. PLoS One. 2014;9(12):e115216.
Higashi N, Mita H, Ono E, Fukutomi Y, Yamaguchi H, Kajiwara K, et al. Profile of eicosanoid generation in aspirin-intolerant asthma and anaphylaxis assessed by new biomarkers. J Allergy Clin Immunol. 2010;125(5):1084–91. e6
O’Shaughnessy KM, Wellings R, Gillies B, Fuller RW. Differential effects of fluticasone propionate on allergen-evoked bronchoconstriction and increased urinary leukotriene E4 excretion. Am Rev Respir Dis. 1993;147(6 Pt 1):1472–6.
Liu MC, Dube LM, Lancaster J. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group. J Allergy Clin Immunol. 1996;98(5 Pt 1):859–71.
Thomson NC, Chaudhuri R, Spears M, Messow CM, Jelinsky S, Miele G, et al. Arachidonic acid metabolites and enzyme transcripts in asthma are altered by cigarette smoking. Allergy. 2014;69(4):527–36.
Rabinovitch N, Reisdorph N, Silveira L, Gelfand EW. Urinary leukotriene E(4) levels identify children with tobacco smoke exposure at risk for asthma exacerbation. J Allergy Clin Immunol. 2011;128(2):323–7.
Murray JJ, Tonnel AB, Brash AR, Roberts LJ 2nd, Gosset P, Workman R, et al. Release of prostaglandin D2 into human airways during acute antigen challenge. N Engl J Med. 1986;315(13):800–4.
O’Sullivan S, Dahlen B, Dahlen SE, Kumlin M. Increased urinary excretion of the prostaglandin D2 metabolite 9 alpha, 11 beta-prostaglandin F2 after aspirin challenge supports mast cell activation in aspirin-induced airway obstruction. J Allergy Clin Immunol. 1996;98(2):421–32.
Nagakura T, Obata T, Shichijo K, Matsuda S, Sigimoto H, Yamashita K, et al. GC/MS analysis of urinary excretion of 9alpha,11beta-PGF2 in acute and exercise-induced asthma in children. Clin Exp Allergy. 1998;28(2):181–6.
Misso NL, Aggarwal S, Phelps S, Beard R, Thompson PJ. Urinary leukotriene E4 and 9 alpha, 11 beta-prostaglandin F concentrations in mild, moderate and severe asthma, and in healthy subjects. Clin Exp Allergy. 2004;34(4):624–31.
Reimert CM, Minuva U, Kharazmi A, Bendtzen K. Eosinophil protein X/eosinophil derived neurotoxin (EPX/EDN). Detection by enzyme-linked immunosorbent assay and purification from normal human urine. J Immunol Methods. 1991;141(1):97–104.
Klonoff-Cohen H, Polavarapu M. Eosinophil protein X and childhood asthma: a systematic review and meta-analysis. Immun Inflamm Dis. 2016;4(2):114–34.
Khalil Kalaajieh W, Hoilat R. Asthma attack severity and urinary concentration of eosinophil X protein in children. Allergol Immunopathol. 2002;30(4):225–31.
Nuijsink M, Hop WC, Sterk PJ, Duiverman EJ, De Jongste JC. Urinary eosinophil protein X in childhood asthma: relation with changes in disease control and eosinophilic airway inflammation. Mediat Inflamm. 2013;2013:532619.
Wu W, Chen Y, d’Avignon A, Hazen SL. 3-Bromotyrosine and 3,5-dibromotyrosine are major products of protein oxidation by eosinophil peroxidase: potential markers for eosinophil-dependent tissue injury in vivo. Biochemistry. 1999;38(12):3538–48.
Wu W, Samoszuk MK, Comhair SA, Thomassen MJ, Farver CF, Dweik RA, et al. Eosinophils generate brominating oxidants in allergen-induced asthma. J Clin Invest. 2000;105(10):1455–63.
Wedes SH, Wu W, Comhair SA, McDowell KM, DiDonato JA, Erzurum SC, et al. Urinary bromotyrosine measures asthma control and predicts asthma exacerbations in children. J Pediatr. 2011;159(2):248–55.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Li, W., Glaum, M.C. (2018). Biomarkers in Severe Asthma. In: Lee, Y., Kim, S., Cho, S. (eds) Severe Asthma. Springer, Singapore. https://doi.org/10.1007/978-981-10-1998-2_4
Download citation
DOI: https://doi.org/10.1007/978-981-10-1998-2_4
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-1997-5
Online ISBN: 978-981-10-1998-2
eBook Packages: MedicineMedicine (R0)